Patient Number Age (years)
Sex
LVEF (%) Follow Up (months)
Arrhythmia
Site of Lymphadenopathy
Lymph nodes with 18FDG-PET uptake
Atrial 18FDG-PET uptake Biopsied Node
PPD
M.tb PCR AFB Culture
Diagnosis
Disease specific therapy
Presentation
CHADS-Vasc score
1 62 M 61 24 AF M, C M, C RA C P N P CS/TB PDN+ATT Symptomatic AF 2
2 53 M 68 26 AF, AFL M M RA, RAA, IAS, LAA, LAPW, LA M N N N CS PDN Symptomatic AFL/AF 2
3 48 F 60 24 AF M M RA M P N N CS PDN Symptomatic AF 1
4 25 M 60 42 AF, AFL, AVNRT M, A M RA, RAA RAA biopsy N N N CS PDN Initially with AVNRT followed by symptomatic AF/AFL 2
5 62 F 32 31 AF M, C M, C RA, RAA, IAS, LAA, LA C N N N CS PDN Heart failure and AF 2
6 37 M 65 28 AF M M RA M N N N CS PDN Symptomatic AF 0
7 42 F 35 22 AF M,S M, S LAA, LAPW, LA S P P NA CS/TB PDN+ATT Heart failure and AF 2
8 58 M 45 42 AF M M RA M P NA P CS/TB PDN+ATT Symptomatic AF 0
9 21 M 54 62 AF M M RA, RAA M N N N CS PDN Symptomatic AF 0
10 42 F 35 51 AF, AFL M M RA M N N N CS PDN Heart failure and AFL 2
11 52 M 36 8 AF M M LAA, LAPW, LA M N N N CS PDN Symptomatic AF 2
12 32 M 39 19 AF, AVNRT M M RA, RAA M N N N CS PDN AF with AVNRT 0
13 28 M 43 24 AF M,C M RA M N N N CS PDN/MT Symptomatic AF 0
14 48 M 49 30 AF, AFL M M RA, RAA M N N N CS PDN Symptomatic AFL 0
15 40 M 39 25 AF M M RA, RAA, LA, LAPW M P N N CS PDN/MT Symptomatic AF 1